A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Study Summary

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Conditions

NSCLC Adenocarcinoma Gastroesophageal Cancer (GC)Gastric Adenocarcinoma Adenocarcinoma of Esophagus Squamous Cell Car. - Esophagus Urothelial Carcinoma (UC)Bladder Cancer Mesothelioma Pleural Mesothelioma Peritoneal Mesothelioma Non-Small Cell Lung Cancer NSCLC

Interventions / Drugs

IDE892 IDE397

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment260 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812128+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.